Risk and Value-Based Contracting for Prescription Drug Therapeutics and Manufacturer’s Support in Utilization

Opinion
Video

Mahsa Salsabili, PharmD, PhD, explores risk and value-based contracting for prescription digital therapeutics, along with strategies for manufacturers to support their utilization and optimization, while also delving into cost-effectiveness modeling and budget impact analysis.

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!
Recent Videos
2 experts in this video
2 experts in this video
Related Content
Stethoscope sitting on money | Image credit: Valeri Luzina - stock.adobe.com

Patients Express Concerns Over Costs, Risks of Gene Therapies for Sickle Cell Disease

Laura Joszt, MA
September 11th 2025
Article

Read More

A gene being edited | Image credit: natali_mis - stock.adobe.com

A Single CRISPR Treatment Could Replace a Lifetime of Daily Treatment in Hereditary Angioedema

Laura Joszt, MA
September 11th 2025
Article

Read More

GVHD wood blocks with pills | Image credit: Dzmitry - stock.adobe.com

New Chronic GVHD Treatments Show Promise, but Long-Term Outcomes Are Not Well Understood

Laura Joszt, MA
September 11th 2025
Article

Read More

Wooden blocks spelling GVHD | Image credit: Stanislau - adobe.stock.com

GVHD Cannot Be Wholly Prevented, so Effective Treatments Are Needed, Says Dr. Daniel Wolff

Laura Joszt, MA
September 11th 2025
Article

Read More

Screenshot of an interview with Michelle Cespedes, M.D.

Evolving Role of Statins in Managing CV Risk in HIV | ID Week 2024

Peter Wehrwein, Managing Editor;Laura Joszt, MA
September 11th 2025
Article

Read More

Female doctor sitting with table and various health care icons | Image credit: stock.adobe.com - ImageFlow

Pulmonary Hypertension Diagnosis on Top of ILD Subsequently Increases Healthcare Use, Costs

Laura Joszt, MA
September 11th 2025
Article

Read More

© 2025 MJH Life Sciences

All rights reserved.